K. Park
About
K. Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, K. Park has authored 25 papers receiving a total of 714 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in K. Park's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). K. Park is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). K. Park collaborates with scholars based in South Korea, United States and Hong Kong. K. Park's co-authors include Tony Mok, Vera Hirsh, Michael Boyer, Jean Fan, James Chih‐Hsin Yang, Luis Paz‐Ares, Angela Märten, Scott A. Laurie, L. Zhang and Kenneth J. O’Byrne and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.
In The Last Decade
K. Park
24 papers receiving 705 citations
Hit Papers
Peers
K. Park
Bente Frimodt‐Moller United States
Jang Ho Cho South Korea
Kosei Tajima Japan
Philip Tracy United States
Jin‐Ji Yang China
Yoshiro Fujiwara Japan
Seisuke Nagase Japan
Sook Jung Jo South Korea
Tzu‐Hsiu Tsai Taiwan
C. Zhou China
Citations per year, relative to K. Park K. Park (= 1×)
peers
Bente Frimodt‐Moller
Countries citing papers authored by K. Park
Since
Specialization
Citations
This map shows the geographic impact of K. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Park more than expected).
Fields of papers citing papers by K. Park
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by K. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Park. The network helps show where K. Park may publish in the future.
Co-authorship network of co-authors of K. Park
This figure shows the co-authorship network connecting the top 25 collaborators of K. Park. A scholar is included among the top collaborators of K. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Park. K. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Paz‐Ares, Luis, Rémi Veillon, Margarita Majem, et al.. (2024). 7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC. ESMO Open. 9. 102586–102586.
2.
Gautschi, Oliver, Alexander Drilon, Benjamin Solomon, et al.. (2024). 35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer. ESMO Open. 9. 102614–102614.
3.
Girard, N., K. Park, Kun Tang, et al.. (2023). LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study. Annals of Oncology. 34. S1304–S1304.
4.
Patel, Jitandrakumar R., et al.. (2023). Cooperative mechanisms underlie differences in myocardial contractile dynamics between large and small mammals. The Journal of General Physiology. 155(11).
5.
Mok, Tony, et al.. (2022). LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Annals of Oncology. 33. S1561–S1562.
6.
Leighl, N. B., Catherine A. Shu, Anna Minchom, et al.. (2021). 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study. Annals of Oncology. 32. S951–S952.
7.
Ku, Bo Mi, Hyun Ae Jung, Jong‐Mu Sun, et al.. (2019). P2.14-61 Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S855–S855.
8.
Garassino, Marina Chiara, Byoung Chul Cho, Julien Mazières, et al.. (2018). P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC. Journal of Thoracic Oncology. 13(10). S467–S468.
9.
Felip, Enriqueta, Makoto Nishio, Sergey Orlov, et al.. (2018). Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3). Annals of Oncology. 29. viii745–viii745.
10.
Corral, J., K. Park, James Chih‐Hsin Yang, et al.. (2017). Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7). Annals of Oncology. 28. ii34–ii34.
11.
Artal, Á., Julien Mazières, Louis Fehrenbacher, et al.. (2017). Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR. Annals of Oncology. 28. ii35–ii35.
12.
Paz‐Ares, Luis, E.H. Tan, Kenneth J. O’Byrne, et al.. (2017). Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. 28(2). 270–277.
13.
Park, K., E.H. Tan, L. Zhang, et al.. (2017). Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7). European Journal of Cancer. 72. S184–S184.
14.
Park, K., E.H. Tan, L. Zhang, et al.. (2016). 440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7). Annals of Oncology. 27. ix140–ix141.
15.
Paz‐Ares, Luis, E.H. Tan, L. Zhang, et al.. (2016). Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7). Annals of Oncology. 27. vi580–vi580.
16.
Schüler, Martin, Kenneth J. O’Byrne, L. Zhang, et al.. (2016). Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial. Annals of Oncology. 27. vi425–vi425.
17.
Park, K., Myung‐Ju Ahn, Chong‐Jen Yu, et al.. (2015). 419O Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) – results from ASCEND-2 and ASCEND-3. Annals of Oncology. 26. ix125–ix125.
18.
Park, K., Joo‐Hang Kim, Martin Schüler, et al.. (2014). Afatinib (A) Followed By a + Paclitaxel (P) or Investigator'S Choice of Single-Agent Chemotherapy (Ic) in Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung: Subgroup Analysis of Lux-Lung 5 (Ll5). Annals of Oncology. 25. iv443–iv443.
19.
Mok, Tony, E.H. Tan, James Chih‐Hsin Yang, et al.. (2014). Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma. Annals of Oncology. 25. iv70–iv70.
20.
Crinò, Lucio, D. Kim, Gregory J. Riely, et al.. (2011). Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.. Journal of Clinical Oncology. 29(15_suppl). 7514–7514.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Bente Frimodt‐Moller Breakdown of academic impact, for papers by Jang Ho Cho Breakdown of academic impact, for papers by Kosei Tajima Breakdown of academic impact, for papers by Philip Tracy Breakdown of academic impact, for papers by Jin‐Ji Yang Breakdown of academic impact, for papers by Yoshiro Fujiwara Breakdown of academic impact, for papers by Seisuke Nagase Breakdown of academic impact, for papers by Sook Jung Jo Breakdown of academic impact, for papers by Tzu‐Hsiu Tsai Breakdown of academic impact, for papers by C. Zhou